The FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
The FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
Read More
An exhalation delivery system plus fluticasone (EDS-FLU) reduced chronic sinus infection (sinusitis) symptoms and decreased infections associated with chronic inflammation of the sinus by more than 50%.
Read MoreIn patients with eosinophilic sinusitis and comorbid bronchial asthma, sinusitis treatment with dupilumab may ease asthma symptoms.
Read More
The Olympus Celeris system contains the only single-use sinus debrider on the market and is indicated for cutting, coagulation, debriding and removal of thin bone and soft tissue in general ENT and sinus/rhinology procedures.
Read More
Biologic asthma treatment improves symptoms of coexisting chronic rhinosinusitis in some patients,...
Read More
Coexisting bronchiectasis in patients with asthma and chronic rhinosinusitis is common and linked with more severe disease, according to new research.
Read More
A new stepped-care treatment algorithm recommends Exhalation Delivery System-fluticasone (EDS-FLU) for the treatment of patients with chronic rhinosinusitis with nasal polyps.
Read More
Despite improvements in surgical technique to limit tissue trauma in chronic rhinosinusitis patients, postoperative challenges can limit endoscopic sinus surgery outcomes, including scarring or stenosis of surgical opening and recurrent inflammation and polyposis.
Read MoreFDA approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) to treat atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).
Read More
The US FDA has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis.
Read More
According to research published in the Journal of Allergy and Clinical Immunology: In Practice, 62% of bronchiectasis patients suffer from chronic rhinosinusitis.
Read More
